NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at ASSFN 2026
Summary
NeuroPace announced its participation in the 2026 American Society for Stereotactic and Functional Neurosurgery Meeting, where it will highlight the expanding role of responsive neuromodulation in epilepsy care. The program will feature thalamic neuromodulation and NAUTILUS data in idiopathic generalized epilepsy, the recently FDA-approved ECoG Assistant AI-enabled tool, and next-generation product development priorities. NeuroPace reported Q1 2026 revenue of $22.1 million, representing 20 percent year-over-year growth.
Why it matters
NeuroPace's continued growth and investment in AI-enabled tools for its RNS System demonstrate the maturation of responsive neurostimulation as a standard of care for drug-resistant epilepsy. The company's progress toward potential indication expansion into generalized epilepsy could significantly broaden its addressable market while its AI-powered ECoG Assistant tool represents an important step toward data-driven personalization of implanted neurostimulation therapy.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial